Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-10-30
2011-11-15
Szperka, Michael (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S326000, C435S328000, C435S336000, C435S069600, C424S133100, C424S141100, C424S145100, C530S387300, C530S388240
Reexamination Certificate
active
08058418
ABSTRACT:
Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
REFERENCES:
patent: 4710457 (1987-12-01), Dupont et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 5891438 (1999-04-01), Silverman
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6419929 (2002-07-01), Anderson
patent: 6479635 (2002-11-01), Anderson et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6562948 (2003-05-01), Anderson
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6645500 (2003-11-01), Halkier et al.
patent: 6740522 (2004-05-01), Anderson
patent: 7097834 (2006-08-01), Boyle
patent: 7364736 (2008-04-01), Boyle et al.
patent: 7411050 (2008-08-01), Anderson
patent: 7449185 (2008-11-01), Yamaguchi et al.
patent: 7527790 (2009-05-01), Yamaguchi et al.
patent: 7718776 (2010-05-01), Boyle et al.
patent: 7744886 (2010-06-01), Anderson
patent: 7923008 (2011-04-01), Boyle
patent: 2002/0150555 (2002-10-01), Gillispie et al.
patent: 2003/0017151 (2003-01-01), Dougall et al.
patent: 2003/0021785 (2003-01-01), Dougall
patent: 2003/0175840 (2003-09-01), Anderson et al.
patent: 2003/0176647 (2003-09-01), Yamaguchi et al.
patent: 2003/0208045 (2003-11-01), Yamaguchi et al.
patent: 2004/0086503 (2004-05-01), Cohen et al.
patent: 2005/0003457 (2005-01-01), Yamaguchi et al.
patent: 032028 (2003-10-01), None
patent: 2002231368 (2002-07-01), None
patent: 0 911 342 (1999-04-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 98/28424 (1998-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/46644 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/58674 (1999-11-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 01/44472 (2001-06-01), None
patent: WO 01/62932 (2001-08-01), None
patent: WO 01/91793 (2001-12-01), None
patent: WO 02/15846 (2002-02-01), None
patent: WO 02/16551 (2002-02-01), None
patent: WO 02/053596 (2002-07-01), None
Janeway et al., Immunobiology, 3rd edition, 1997, Garland Press, pp. 3:1 to 3:11.
William E. Paul, M.D. ed., Fundamental Immunology, 3d ed. 1993, p. 242.
Portolano et al., J. Immunol., 1993, 150:880-887.
Rudikoff et al., Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature, 390:175-179 (1997).
Body et a., “A Study of the Biological Receptor Activator of Nuclear Factor-κB Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer,”Clin. Cancer Res. 2006, 12(4):1221-1228 (2006).
Hofbauer et al., “The Role of Receptor Activator of Nuclear Factor -κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Disease,”J. of Clin. Endocrin. Metab., 85:2355-2363 (2000).
Kinpara et al., “Osteoclast differentiation factor in human osteosarcoma cell line,”J. Immunoassay, 21:327-340 (2000).
Kodaira et al., “Cloning and characterization of the gene encoding mouse osteoclast differentiation factor,”Gene, 230:121-127 (1999).
Kong et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, 397:315-323 (1999).
Kong et al., “Osteoprotegerin ligand: a regulator of immune responses and bone physiology,”Immun. Today, 21(10): 495-502 (2000).
Lacey et al., “Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation,”Cell, 93:165-176 (1998).
Lacey et al., “Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo,”Am. J. Pathol., 157:435-448 (2000).
Nakagawa et al., “RANK is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis,”Biochem. Biophys. Res. Comm., 253:395-400 (1998).
Stressgen product use sheet for product No. AAM-425AF, Mouse Anti-TRANCE Monoclonal Antibody clone No. 12A668, revised Jun. 27, 2005.
Takahashi et al., “A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function,”Biochem. Biophys. Res. Comm., 256(3):449-455 (1999).
Tsukii et al., “Osteoclast Differentiation Factor Mediates an Essential Signal for Bone Resorption Induced by 1 alpha, 25-Dihydroxyvitamin D3, Prostaglandin E2, or Parathyroid Hormone in the Microenvironment of Bone,”Biochem. Biophys. Res. Comm., 246(2):337-341 (1998).
Wong et al., “TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family that Activates c-Jun N-Terminal Kinase in T Cells,”J. Biol. Chem., 272:25190-25194 (1997).
Wong et al., “TRANCE (Tumor Necrosis Factor [TNF]-related Activation-Induced Cytokine), a New TNF Family Member Predominantly Expressed in T Cells, Is a Dentritic Cell-specific Survival Factor, ”J. Exp. Med., 186:2075-2080 (1997).
Yasuda et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,”Proc. Natl. Acad. Sci. USA, 95:3597-3602 (1998).
Response with Exhibits A and B filed in U.S. Appl. No. 09/211,315 on Aug. 18, 2000.
Office Action in U.S. Appl. No. 09/718,726 mailed on Jun. 4, 2003.
Office Action in U.S. Appl. No. 09/211,297 mailed on Mar. 27, 2003.
Preliminary Amendment filed in U.S. Appl. No. 09/466,496 on Dec. 17, 1999.
Office Action in U.S. Appl. No. 09/466,496 mailed on Jul. 31, 2001.
Amendment and Response to Office Action filed in U.S. Appl. No. 09/466,496 on Nov. 29, 2001.
Supplemental Amendment filed in U.S. Appl. No. 09/466,496 on Feb. 22, 2002.
Amendment and Response to Office Action filed in U.S. Appl. No. 09/466,496 on Aug. 6, 2002.
Preliminary Amendment filed in U.S. Appl. No. 09/577,800 on May 24, 2000.
Third Preliminary Amendment filed in U.S. Appl. No. 09/577,800 on Jul. 26, 2001.
Preliminary Amendment filed in U.S. Appl. No. 09/871,856 on May 31, 2001.
Second Preliminary Amendment filed in U.S. Appl. No. 09/871,856 on Dec. 12, 2002.
Amendment and Response to Paper No. 12 with Exhibits A to D, filed in U.S. Appl. No. 09/705,985 on Apr. 3, 2003.
Communication pursuant to Article 96(2) EPC in European Patent Application No. 02 749 660.3—1222 dated Jun. 9, 2006.
First Office Action and Text of the First Office Action in Chinese Patent Application No. 02816680.9, dated Feb. 24, 2006, with English translation.
English Translation of Office Action in Taiwan Patent Application No. 91114055, dated Sep. 7, 2005.
Examiner's first report dated Jan. 30, 2007, in Australian Patent Application No. 2002320157.
Official Notification on the necessity of submitting additional materials dated Sep. 4, 2006, in Eurasian Patent Application No. 200400063/28, with English translation.
Office Action in U.S. Appl. No. 10/180,648 mailed on Apr. 29, 2005.
Amendment and Response to Office Action (Restriction Requirement) filed in U.S. Appl. No. 10/180,648 on Jul. 29, 2005.
Examiner-Initiated Interview Summary in U.S. Appl. No. 10/180,648 mailed on Sep. 27, 2005.
Applicant Statement of Interview Summary filed in U.S. Appl. No. 10/180,648 on Oct. 14, 2005.
Office Action in U.S. Appl. No. 10/180,648 mailed on Oct. 21, 2005.
Amendment and Response filed in U.S. Appl. No. 10/180,648 on Jan. 25, 2006.
Office Action in U.S. Appl. No. 10/180,648 mailed on Apr. 18, 2006.
Amendment After Final filed in U.S. Appl. No. 10/180,648 on Jul. 18, 2006.
Advisory Action Before the Filing of an Appeal Brief in U.S. Appl. No. 10/180,648 mailed on Aug. 7, 2006.
Amendment filed in U.S. Appl.
Boyle William J.
Corvalan Jose R.
Davis C. Geoffrey
Martin Francis H.
Amgen Fremont Inc.
Amgen Inc.
Finnegan Henderson Farabow Garrett and Dunner, LLP
Szperka Michael
LandOfFree
Polynucleotides encoding heavy and light chains of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding heavy and light chains of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding heavy and light chains of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283243